Zydus Wellness Limited has informed the Exchange about Investor Presentation
ZYDUSWELL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Wellness reported FY25 net sales of ₹26,912 mn, up 16.2% YoY, and Q4 FY25 net sales of ₹9,106 mn, up 17% YoY. FY25 EBITDA grew 23.2% to ₹3,797 mn with margin expanding to 14.0% (from 13.2%), and Q4 FY25 EBITDA margin held at 20.8%. Profit after tax for FY25 rose 30% to ₹3,469 mn. The company guided to 17-18% EBITDA margin in 2-3 years, targets doubling of sales in 3-5 years, and aims for net cash positive by mid-FY26. The Board recommended a ₹6 final dividend (20% increase) and a 1:5 stock split, both subject to shareholder approval. The Naturell (India) acquisition completed earlier is performing as planned, and the company said it remains open to future acquisitions.
Strong revenue and margin growth, along with explicit forward targets, signal improving earnings trajectory for shareholders. The 20% dividend hike and proposed 1:5 stock split should improve share liquidity and retail participation, likely to be viewed positively by the market.